Koers Inotek Pharmaceuticals Corp Nasdaq
Aandelen
US45780V1026
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- | - |
Omzet 2024 * | 29,54 mln. 0 27,45 mln. | Omzet 2025 * | 186 mln. 0 173 mln. | Marktkapitalisatie | 2,13 mld. 0 1,98 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -262 mln. - -243 mln. | Nettowinst (verlies) 2025 * | -217 mln. - -202 mln. | EV/omzet 2024 * | 66,6 x |
Nettoliquiditeiten 2024 * | 163 mln. 0 152 mln. | Nettoliquiditeiten 2025 * | 59,29 mln. 0 55,1 mln. | EV/omzet 2025 * | 11,1 x |
K/w-verhouding 2024 * |
-8,83
x | K/w-verhouding 2025 * |
-12,5
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 94,69% |
Recentste transcriptie over Inotek Pharmaceuticals Corp
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Gaurav D. Shah
CEO | Chief Executive Officer | 49 | 04-01-18 |
Kinnari Patel
PSD | President | 46 | 04-01-18 |
Chief Tech/Sci/R&D Officer | 60 | 01-01-16 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Pedro Granadillo
BRD | Director/Board Member | 77 | 04-01-18 |
Carsten Boess
BRD | Director/Board Member | 57 | 01-01-16 |
David Southwell
BRD | Director/Board Member | 63 | 01-08-14 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-1,43% | 104 mld. | |
+8,96% | 105 mld. | |
+4,40% | 22,94 mld. | |
-12,15% | 22,34 mld. | |
-4,36% | 19,25 mld. | |
-39,98% | 17,08 mld. | |
-10,04% | 16,96 mld. | |
+6,79% | 14,16 mld. | |
+38,61% | 12,63 mld. |
- Beurs
- Aandelen
- Koers RCKT
- Koers